The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: A meta-analysis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Xie, Qingsong ^a,b,c   Zhou, Xiaohu ^a,b,c   Huang, Pengfei ^a,b,c   Wei, Jianfeng ^a,b,c   Wang, Weilin ^a,b,c   Zheng, Shusen ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENHANCED LIVER FIBROSIS TESTT; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BIOPSY; ELASTOGRAPHY; META ANALYSIS; PATHOLOGY; REPRODUCIBILITY; RISK; SEVERITY OF ILLNESS INDEX;

BIOPSY; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS; ODDS RATIO; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84899667604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092772     Document Type: Article

References (53)

1. National Institutes of Health Consensus Development Conference (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002; June 10-12, 2002; Hepatology 36: S3-20.
2. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495-500.
3. Castera L, Negre I, Samii K, Buffet C (1999) Pain experienced during percutaneous liver biopsy. Hepatology 30: 1529-1530.
4. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457.
5. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, et al. (2005) Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41: 257-264.
6. Afdhal NH (2003) Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 37: 972-974.
7. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
8. Afdhal NH, Nunes D (2004) Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99: 1160-1174.
9. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29: 1705-1713.
10. Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, et al. (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51: 828-835.
11. Eriksson S, Fraser JR, Laurent TC, Pertoft H, Smedsrod B (1983) Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 144: 223-228.
12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
13. Arthur MJ, Mann DA, Iredale JP (1998) Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 13 Suppl: S33-38.
14. Prakobwong S, Pinlaor S, Yongvanit P, Sithithaworn P, Pairojkul C, et al. (2009) Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int J Parasitol 39: 825-835.
15. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, et al. (1998) Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 153: 1895-1902.
16. Herbst H, Wege T, Milani S, Pellegrini G, Orzechowski HD, et al. (1997) Tissue inhibitor of metalloproteinase-1 and-2 RNA expression in rat and human liver fibrosis. Am J Pathol 150: 1647-1659.
17. Kivirikko KI, Myllyla R (1985) Post-translational processing of procollagens. Ann N Y Acad Sci 460: 187-201.
18. Horslev-Petersen K (1990) Circulating extracellular matrix components as markers for connective tissue response to inflammation. A clinical and experimental study with special emphasis on serum aminoterminal type III procollagen peptide in rheumatic diseases. Dan Med Bull 37: 308-329.
19. Entzian P, Huckstadt A, Kreipe H, Barth J (1990) Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome. Am Rev Respir Dis 142: 1079-1082.
20. Waydhas C, Nast-Kolb D, Trupka A, Lenk S, Duswald KH, et al. (1993) Increased serum concentrations of procollagen type III peptide in severely injured patients: an indicator of fibrosing activity? Crit Care Med 21: 240-247.
21. Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, et al. (2013) Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One 8: e59088.
22. Yoo EJ, Kim BK, Kim SU, Park JY, Kim do Y, et al. (2013) Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. Liver Int 33: 706-713.
23. Janciauskiene S, Wallmark A, Piitulainen E, Kohnlein T, Welted T, et al. (2011) Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ alpha1-antitrypsin deficiency. Eur J Gastroenterol Hepatol 23: 716-720.
24. National Institute for Health Research National Horizon Scanning Centre (2008) Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. Birmingham: National Horizon Scanning Centre 2008.
25. Whiting P, Rotes AW, Reitman JB, Bossuet PM, Keenen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25.
26. Hollingworth W, Medina LS, Lenkinski RE, Shibata DK, Bernal B, et al. (2006) Interrater reliability in assessing quality of diagnostic accuracy studies using the QUADAS tool. A preliminary assessment. Acad Radiol 13: 803-810.
27. Whiting P, Harbord R, de Salis I, Egger M, Sterne J (2008) Evidence-based diagnosis. J Health Serv Res Policy 13 Suppl 3: 57-63.
28. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
29. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuet PM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56: 1129-1135.
30. Reitman JB, Glas AS, Rotes AW, Scholten RJ, Bossuet PM, et al. (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58: 982-990.
31. Chu H, Cole SR (2006) Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 59: 1331-1332; author reply 1332-1333.
32. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, et al. (2009) Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 136: 160-167.
33. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455-460.
34. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, et al. (2010) Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 10: 103.
35. Parkes J, Guha IN, Roderick P, Harris S, Cross R, et al. (2011) Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 18: 23-31.
36. Guechot J, Trocme C, Renversez JC, Sturm N, Zarski JP (2012) Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 50: 693-699.
37. Kim BK, Kim HS, Park JY, Kim do Y, Ahn SH, et al. (2012) Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One 7: e41964.
38. Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K, et al. (2012) Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One 7: e51906.
39. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, et al. (2013) The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatol 59: 236-242.
40. Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, et al. (2014) Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 39: 197-208.
41. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
42. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology 134: 960-974.
43. Berenguer M (2009) Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: can we avoid liver biopsies? Dig Liver Dis 41: 226-228.
44. Kamphues C, Lotz K, Rocken C, Berg T, Eurich D, et al. (2010) Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. Clin Transplant 24: 652-659.
45. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408.
46. The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15-20.
47. Parkes J, Roderick P, Harris S, Day C, Mutimer D, et al. (2010) Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59: 1245-1251.
48. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, et al. (2008) Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48: 1549-1557.
49. Trepo E, Potthoff A, Pradat P, Bakshi R, Young B, et al. (2011) Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 55: 38-44.
50. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
51. Guha IN, Myers RP, Patel K, Talwalkar JA (2011) Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology 54: 1454-1462.
52. Mehta SH, Lau B, Afdhal NH, Thomas DL (2009) Exceeding the limits of liver histology markers. J Hepatol 50: 36-41.
53. Cholongitas E, Quaglia A, Samonakis D, Senzolo M, Triantos C, et al. (2006) Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 55: 1789-1794.